- Home
- DMA vs IGMS Comparison
DMA vs IGMS Comparison
Compare DMA & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMA
- IGMS
- Stock Information
- Founded
- DMA 2011
- IGMS 1993
- Country
- DMA United States
- IGMS United States
- Employees
- DMA N/A
- IGMS N/A
- Industry
- DMA Trusts Except Educational Religious and Charitable
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- DMA Finance
- IGMS Health Care
- Exchange
- DMA Nasdaq
- IGMS Nasdaq
- Market Cap
- DMA 72.0M
- IGMS 82.1M
- IPO Year
- DMA N/A
- IGMS 2019
- Fundamental
- Price
- DMA $8.46
- IGMS $1.13
- Analyst Decision
- DMA
- IGMS Hold
- Analyst Count
- DMA 0
- IGMS 8
- Target Price
- DMA N/A
- IGMS $6.14
- AVG Volume (30 Days)
- DMA 34.6K
- IGMS 155.8K
- Earning Date
- DMA 01-01-0001
- IGMS 05-20-2025
- Dividend Yield
- DMA 2.04%
- IGMS N/A
- EPS Growth
- DMA N/A
- IGMS N/A
- EPS
- DMA N/A
- IGMS N/A
- Revenue
- DMA N/A
- IGMS $2,679,000.00
- Revenue This Year
- DMA N/A
- IGMS $121.76
- Revenue Next Year
- DMA N/A
- IGMS $46.83
- P/E Ratio
- DMA N/A
- IGMS N/A
- Revenue Growth
- DMA N/A
- IGMS 25.77
- 52 Week Low
- DMA $4.78
- IGMS $0.92
- 52 Week High
- DMA $8.00
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- DMA 57.65
- IGMS 39.53
- Support Level
- DMA $8.25
- IGMS $1.11
- Resistance Level
- DMA $8.54
- IGMS $1.40
- Average True Range (ATR)
- DMA 0.20
- IGMS 0.11
- MACD
- DMA 0.05
- IGMS -0.01
- Stochastic Oscillator
- DMA 79.30
- IGMS 5.56
About DMA Destra Multi-Alternative Fund
Destra Multi-Alternative Fund is a non-diversified, closed-end management investment company that operates as an interval fund with a continuous offering of fund shares. The investment objective of the fund is to seek returns from capital appreciation and income with an emphasis on income generation.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.